JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib. Reversine, a multikinase inhibitor selective for aurora kinases, reduced cell viability in a dose- and/or time-dependent manner in JAK2V617F cells. Reversine significantly increased apoptosis and mitotic catastrophe, and reduced cell proliferation and clonogenic capacity in SET2 and HEL cells. In the molecular scenario, reversine induced DNA damage and apoptosis markers, as well as, reduced AURKA and AURKB expression/activity. In SET2 cells, reversine modulated the expression of 32 out of 84 apoptosis-related genes investigated, including downregulation of antiapoptotic (BCL2, BCL2L1, and BIRC5) and upregulation of proapoptotic (BIK, BINP3, and BNIP3L) genes. Synergism experiments indicated that low dose of reversine had a potentiating effect under ruxolitinib treatment at low doses in SET2 cells. In summary, our exploratory study establishes new targets, related to the regulation of the cellular cytoskeleton, for potential pharmacological intervention in MPN. These findings indicate that AURKA and AURKB participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.
Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are characterized by excessive myeloid progenitor proliferation that keeps terminal differentiation capacity and have heightened risk of bone marrow failure or acute myeloid leukemia transformation1. The most frequent MPN are essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), which present a high incidence of JAK2 activating mutations (i.e. JAK2V617F, indel CALR, and MPL mutations)2. At the cellular level, the constitutive activation of the JAK2/STAT pathway leads to hypersensitive or independence of cytokines or growth factor, which contributes to cell proliferation, survival, and differentiation3,4. Thus, JAK2/STAT signaling pathway plays a central role in the MPN pathophysiology5 and has been targeted by ruxolitinib, a selective JAK1/2 inhibitor approved for the treatment of intermediate and high-risk PMF and PV patients that provides some clinical benefits, but does not lead to complete remission of these diseases and fails to eliminate the malignant clone6,7,8,9.
Previous studies from our research group have shown that the treatment with ruxolitinib modulates the activity of cytoskeleton-related proteins in JAK2V617F cells10. Given that cellular cytoskeleton regulator proteins play vital functions and are often pharmacological targets in the treatment of several solid and hematological neoplasms11, the effects of ruxolitinib in this context deserve further exploration.
In the present study, we investigated the impact of the treatment with ruxolitinib on cytoskeleton-related genes expression and we identified aurora kinase A (AURKA) and B (AURKB) as promising targets for pharmacological intervention in MPN cellular models. The aurora kinase family comprises three serine/threonine kinases (AURKA, AURKB, and AURKC) that play an essential role in cell cycle progression during mitosis and cytokinesis, and their aberrant expression/activation have been related to the malignant phenotype of solid and hematological cancers12,13,14,15.
As a strategy for dual inhibition of AURKA and AURKB, reversine [2-(4-morpholinoanilino)-6-cyclohexylaminopurine] was employed. Reversine is a small synthetic purine analogue that induces mitotic catastrophe, cell-cycle arrest, polyploidy, and apoptosis in several cancer models16,17,18,19. Herein, we described the molecular and cellular effects of the treatment with reversine in the context of JAK2V617F-positive MPN.
Pharmacological inhibition of JAK2/STAT signaling reduces AURKA and AURKB expression in JAK2V617F-positive cell line
To initiate the exploratory study of the molecular effects of the treatment with ruxolitinib on cytoskeleton-related genes of JAK2V617F positive cells, we first investigated the expression of 84 cytoskeleton-related genes in the RNA-Seq data from Meyer et al.20 (GSE69827). Using the cutoff of 1.5-fold for either direction, we found 30 genes differentially expressed (19 downregulated and 11 upregulated) in SET2 after the treatment with ruxolitinib for 48 hours (Fig. 1A). Since AURKA and AURKB gene expression has been associated with the activation of tyrosine kinase signaling in MPN, presented potential contribution to the malignant phenotype, and are putative druggable21,22,23, we selected these two genes for further validation. In SET2 cells, qPCR and Western blotting analysis confirmed that ruxolitinib reduces AURKA and AURKB expression in a dose- and time-dependent manner (Fig. 1B,C).
Reversine induces apoptosis in SET2 and HEL cells
Based on our findings that AURKA and AURKB were downregulated by JAK1/2 inhibitor, ruxolitinib, we investigated the effects of aurora kinases inhibition, by reversine, on cell viability in JAK2V617F-positive cell lines. The treatment with reversine reduced cell viability in a dose- and time-dependent manner (Fig. 2A). Using a nonlinear regression analysis, the IC50 values for reversine in SET2 were 23.6, 4.0, and 3.1 µM, and in HEL cells, they were 28.9, 13.4, and 11.8 µM at 24, 48 and 72 hours, respectively. In both JAK2V617F-positive cell lines analyzed, reversine strongly induces apoptosis in a dose-dependent manner (p < 0.05; Fig. 2B,C).
Next, we checked whether reversine-induced cytotoxicity could be affected by the treatment in combination with ruxolitinib. In SET2 cells, but not in HEL cells, low concentrations of reversine (2.5 μM) and ruxolitinib (<300 nM) combined showed potentiating effects in reducing cell viability (p < 0.001); Fig. 2D and Supplementary Fig. 1.
Reversine decreases proliferation, clonogenicity, and cell cycle progression in JAK2V617F-positive cells
Since aurora kinases are key proteins for cell cycle progression and success of cell division, we investigated the proliferation, clonogenicity, and cell cycle progression upon reversine exposure of JAK2V617F cells. In SET2 and HEL cells, Ki-67 analysis revealed that short-time treatment with reversine significantly reduced cell proliferation (Fig. 3A) and autonomous clonal growth capacity (Fig. 3B), whereas long-term exposure to reversine completely inhibited colony formation in all concentration analyzed (Supplementary Fig. 2). The treatment with reversine significantly induces cell cycle arrest in G2/M phase in both JAK2V617F cell lines (Fig. 3C,D).
Reversine modulates apoptosis-related genes in JAK2V617F-positive cells
In the molecular scenario, reversine reduces AURK activity, as observed by the reduction in histone H3S10 phosphorylation, and increases markers of DNA damage (H2A.X phosphorylation) and apoptosis (cleaved caspase 3) (Fig. 4A). In SET2, but not in HEL cells, AURKA and AURKB mRNA downregulation upon the reversine was observed (Supplementary Fig. 3). Corroborating these data, morphological analysis indicates the presence of mitotic catastrophe and nuclear fragmentation (Fig. 4B).
In order to obtain additional insights about the molecular mechanisms involved in reversine-induced apoptosis, we investigated the expression of apoptosis-related genes in SET2 cells upon the treatment with reversine. A total of 32 different genes demonstrated a change in the expression of ≥1.5-fold in either direction compared to untreated cells: 6 downregulated genes (TNFRSF21, BCL2, TNFRSF10A, BIRC5, BCL2L1, and FAS) and 26 upregulated genes (CASP10, BCL10, GADD45A, CD70, TP53BP2, CASP6, BNIP3, TNFRSF9, BCL2A1, BIRC2, NOD1, DAPK1, CASP9, BIRC3, BIK, NAIP, NOL3, CRADD, TRADD, IGF1R, BCL2L2, CD40LG, LTA, BNIP3L, HRK, and TNFRSF11B) (Fig. 4C; Supplementary Table 1). Based on the cytotoxic effect previously observed, three downregulated-antiapoptotic genes (BCL2, BCL2L1, and BIRC5) and three upregulated-proapoptotic genes (BNIP3, BNIP3L, and BIK) were selected for validation in a larger number of experiments using SET2 and HEL cells, by qPCR. In SET2, but not in HEL cells, reduced BCL2 and BIRC5 expression and increased BNIP3, BNIP3L, and BIK expression upon the treatment with reversine were observed (all p < 0.01); BCL2L1 expression was downregulated in both JAK2V617F cell lines (p < 0.01, Fig. 4D).
Herein, we have investigated the effects of ruxolitinib on cytoskeleton-related genes in JAK2V617F-driven cellular models and a modulation of AURKA and AURKB was found. A previous study reported that JAK2V617F mutant protein activates MYC/AURKA axis, which was identified to be critical for the malignant phenotype maintenance and chemotherapy resistance in transformed-Ba/F3 cells22. Similarly, Wen et al. reported that AURKA is upregulated in primary cells from MPN patients and that the genetic or pharmacological inhibition of AURKA reduces bone marrow fibrosis in JAK2V617F- and MPLW515L-driven models23. In STAT5BN642H-driven T cell neoplasia, AURKB is overactivated and represents potential therapeutic target24. Although the role of AURKA in JAK2V617F-mediated signaling is well described in the literature22,23, the functions of AURKB remain largely unknown in the context of MPN. Exploring microarray data containing gene expression profile of whole blood samples from MPN and healthy donors25 by GEOR2 (https://www.ncbi.nlm.nih.gov/geo/geo2r/), we found that both AURKA and AURKB are upregulated in PMF patients (GEO accession GSE26049; Supplementary Fig. 4), what corroborates previous studies22,23 and provides new insights for AURKB in MPN.
In the present study, AURKA and AURKB were pharmacologically targeted by reversine, a purine analogue that presents antineoplasic effects on multiple models of cancer26, including acute myeloid leukemia (AML)27, multiple myeloma16, and chronic myeloid leukemia (CML)21. Reversine reduced cell viability, proliferation, and cell cycle progression in JAK2V617F cells. Exposure to reversine strongly inhibited autonomous growth, a characteristic that is usually associated with aggressiveness in hematological malignancies28,29, in SET2 and HEL cells. A modest potentiating effect was observed with the combination of low concentrations of reversine and ruxolitinib, corroborating the hypothesis that ruxolitinib inhibits AURK-mediated signaling in MPN models.
In JAK2V617F cells, reversine reduced AURKA and AURKB expression/activity and induced DNA damage and apoptosis markers, which was similar to the one observed for AML and CML cell lines21,27. In SET2, but not in HEL cells, we observed downregulation of BCL2 and BIRC5 (antiapoptotic) and upregulation of BNIP3, BNIP3L, and BIK (proapoptotic) upon the treatment with reversine; BCL2L1 (also known as BCL-XL) was downregulated in both JAK2V617F cells tested. These findings pave avenues to identify unrecovered molecular effects of reversine on cancer cells. It is well defined that BCL2 family plays an important role in MPN: STAT proteins are transcription factors that induce BCL2 and BCL2L1 expression, which promotes cell survival30,31,32. Thus, the modulation of the BCL2 family after exposure to reversine may contribute to a key axis to determine the potency of the drug in JAK2V617F cells. Indeed, some differences in the potency of reversine on cell viability, proliferation, and cell progression reduction between HEL and SET2 cells were observed. Of note, HEL cells are derived from an erythroleukemia patient33, featuring faster growth and resistant to JAK2 inhibitors in vitro, while SET2 cells are derived from an ET patient with leukemic transformation34, featuring slower growth and sensibility to JAK2 inhibitors in vitro. An interesting finding is that, in HEL cells, unlike what was observed in SET2 cells, inhibition of JAK2/STAT signaling by ruxolitinib did not strongly reduce the AURKA and AURKB expression/activation (Supplementary Fig. 5), which is consistent with failure to respond to ruxolitinib in cell viability assays. Thus, in the light of our results, further studies are needed to verify whether the AURK downregulation in the context of JAK2 inhibitors could be a predictor of therapeutic response in MPN patients. Despite differences in reversine potency between HEL and SET2, our findings support results from previous studies concluding that pharmacological inhibition of aurora kinases is a promising strategy in MPN35,36 and provides novel mechanistic insights.
Reversine is a multikinase inhibitor which, in addition to presenting selectivity for aurora kinases, has a high inhibitory potential for MPS137 and JNK38. In view of the promising data of reversine in MPN cellular models, and the opportunity to identify new potential targets for these diseases, the effects of additional selective inhibitors for AURKA, AURKB, MPS1, and JNK were tested and all this inhibitor reduced cell viability with differences in their potencies (Supplementary Fig. 6) Of note, JNK, AURK, and MPS1 signaling pathways present cross-talk contributing to cell cycle progression. JNK acts upstream to AURKB39, whereas AURKB potentiates MPS1 activation40. Thus, our findings highlight that the multitarget effects of reversine may be attractive in diseases in which this signaling axis is activated.
In summary, our exploratory study establishes new targets related to regulation of cellular cytoskeleton for potential pharmacological intervention in MPN. In JAK2V617F cells, the multikinase inhibition, including AURKA and AURKB, by reversine, may be a strategy to block cell cycle progression and reduce cell survival. Our findings corroborate the hypothesis that aurora kinases, particularly AURKA and AURKB, participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.
Material and Methods
RNA-seq data analysis
RNA-seq data was obtained from Meyer et al.20, which was deposited in GEO database (https://www.ncbi.nlm.nih.gov/geo; GEO accession GSE69827). The expression of 84 cytoskeleton-related genes in samples from naïve SET2 cells (GSM1817344, GSM1817345, and GSM1817346) and ruxolitinib-treated SET2 cells (GSM1817332, GSM1817333, and GSM1817334) was investigated. Three replicates for each condition were available. Gene expression was expressed as fold change of the mean of normalized counts of naïve SET2 cells, which was set as 1. Genes that presented mean ≥1.5-fold either direction were included in the heatmap using multiple experiment viewer (MeV) 4.9.0 software (http://mev.tm4.org). The full list of genes included, normalized counts, and relative expression values are described in Supplementary Table 2.
Cell culture and inhibitors
SET2 cells were kindly provided by Prof. Dr. Fabíola Attié de Castro (School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil). HEL was obtained from ATCC (Philadelphia, PA, USA). SET2 and HEL cells harboring JAK2V617F mutation were tested and authenticated by Short Tandem Repeat (STR) matching analysis using the PowerPlex® 16 HS system (Promega, Madison, WI, USA) and the ABI 3500 Sequence Detector System (Life Technologies, Foster City, CA, USA). Cell culture conditions were performed in accordance with the recommendations of ATCC and DSMZ. All cell lines were mycoplasma-free. Ruxolitinib was obtained from InvivoGen (San Diego, CA, USA). Reversine was obtained from TargetMol (Target Molecule Corp., Boston, MA, USA). Aurora-A Inhibitor I (SML0882), AZD1152-HQPA (SML0268), NMS-P715 (475949) and SP600125 (S5567) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Quantitative PCR (qPCR)
Total RNA was obtained using TRIzol reagent (Thermo Fisher Scientific). The cDNA was synthesized from 1 µg of RNA using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR (qPCR) was performed with an ABI 7500 Sequence Detector System using the TaqMan system for AURKA (Hs00269212.m1), AURKB (Hs00177782.m1), ATCB (4310881E-1008027), and GUS (43108881E-0905024) genes (Life Technologies) or SyberGreen System for AURKA, AURKB, BCL2, BCL2L1, BIRC5, BNIP3, BNIP3L, and BIK (Supplementary Table 3). ATCB, GUS, and/or HPRT1 were the reference genes. The relative quantification value was calculated using the equation 2−ΔΔCT. A negative ‘No Template Control’ was included for each primer pair.
Western blot analysis
Equal amounts of protein were used as total extracts, followed by SDS-PAGE, Western blot analysis with the indicated antibodies and imaging using the SuperSignal™ West Dura Extended Duration Substrate System (Thermo Fisher Scientific, San Jose, CA, USA) and Gel Doc XR+ system (Bio-Rad, Hercules, CA, USA) or G:BOX Chemi XX6 gel doc systems (Syngene, Cambridge, UK). Antibodies against STAT3 (sc-7179), STAT5 (sc-835), AURKA (sc-25425), AURKB (sc-25426), phospho (p)-histone H3S10 (sc-8659-R), and p-histone H2A.XS139 (γ-H2A.X; sc-517348) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against p-STAT3Y705 (#9131S), p-STAT5Y694 (#9359S), and caspase 3 (#9665) were obtained from Cell Signaling Technology (Danvers, MA, USA). Cropped gels retain important bands, but whole gel images are available in Supplementary Fig. 7.
Cell viability assay
Cell viability was measured by methylthiazoletetrazolium (MTT) assay. SET2 (4 × 104 cells/well) and HEL cells (2 × 104 cells/well) were cultured in a 96-well plate in RPMI medium containing 10% or 20% FBS, respectively, in the presence of graded concentrations of reversine (1, 2.5, 5, 10, 25, and 50 μM) for 24, 48, and 72 hours. DMSO (Ø) was used as a negative control. IC50 values were calculated using a nonlinear regression analysis on GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). For combined treatment analysis, SET2 and HEL cells were treated with graded doses of reversine (1, 2.5, 5, 10, 25, and 50 μM) and ruxolitinib (3, 10, 30,100, 300, and 1000 nM) alone or in combination with each other for 48 hours and data were illustrated using multiple experiment viewer (MeV) 4.9.0 software (http://www.tm4.org/mev/).
SET2 and HEL were seeded in 24-well plates and treated with graded concentrations of reversine (1, 2.5, 5, 10, 25, and 50 μM) for 48 hours. Cells were then washed twice with ice cold PBS and resuspended in binding buffer containing 1 μg/mL 7AAD and 1 μg/mL FITC-labeled annexin V. All specimens were acquired by flow cytometry (FACSCalibur; Becton Dickinson) after incubation for 15 minutes at room temperature in a light-protected area and analyzed using FlowJo software (Treestar, Inc., San Carlos, CA, USA).
Assessment of cell proliferation by Ki-67 staining
HEL and SET2 cells were treated with reversine (1, 2.5, 5, and 10 μM) for 24 hours, fixed with 70% ethanol and stored at −20 °C. Ki-67 staining was performed following the manufacturer’s instructions (Ki-67 FITC clone B56; BD Bioscience, San Jose, CA, USA) and the mean of fluorescence intensity (M.F.I.) was obtained by flow cytometry using a FACSCalibur instrument (Becton-Dickinson) and analyzed using FlowJo software (Treestar, Inc.). IgG isotype was used as negative control for each condition.
Colony formation assay
Colony formation capacity was evaluated out in semisolid methylcellulose medium (2.5 × 103 cells/mL for SET2 cells; 1 × 103 cells/mL for HEL cells; MethoCult 4230; StemCell Technologies Inc., Vancouver, BC, Canada) after reversine exposure for 36 hours (equal number of viable cells were plated for each condition). Additionally, long-term exposure was also evaluated. Colonies were detected after 10 days of culture by adding 1 mg/mL of MTT reagent and scored by Image J quantification software (U.S. National Institutes of Health, Bethesda, MD, USA).
Cell cycle analysis
SET2 and HEL cells were treated with reversine (1, 2.5, 5, and 10 μM) for 24 hours, fixed with 70% ethanol and stored at 4 °C for at least 2 hours. Then, fixed cells were stained with 20 μg/mL propidium iodide (PI) containing 10 μg/mL RNase A for 30 min at room temperature. DNA content distribution was acquired in a FACSCalibur cytometer (Becton-Dickinson) and analyzed using FlowJo software (Treestar, Inc.).
SET2 and HEL cells, treated or not with 5 μM reversine for 24 hours, were attached on cover slips coated with poly-L-lisine (1 mg/mL), fixed with 3.7% formaldehyde, permeabilized with 0.5% Triton X-PBS and blocked with 3% bovine serum albumin (BSA) PBS. Cells were then incubated with anti-α-tubulin Alexa Fluor® 488 conjugate (1:100 in 3% BSA PBS, Thermo Fisher Scientific) for 12 hours, and followed by PBS wash. The slides were mounted in ProLong Gold Anti-Fade Mounting Medium with DAPI (Thermo Fisher Scientific). Images were generated using fluorescence microscopy (Axio observer; Carl Zeiss, Welwyn Garden City, UK).
PCR array profiling of apoptosis signaling-related genes
Total RNA from SET2 cells treated reversine (5 μM) for 24 hours was obtained using TRIzol reagent (Thermo Fisher Scientific). The cDNA was synthesized from 2 µg of RNA using RT2 First Strand Kit (Qiagen Sciences Inc., Germantown, MD, USA. PCR array was performed using the Human Apoptosis RT2 Profiler PCR Array kit (#PAHS-012ZA; Qiagen Sciences Inc.) according to the manufacturer’s instructions. The mRNA levels were normalized to those detected in untreated cells, and genes that presented a fold change ≥1.5-fold in any treatment were included in the heatmap using multiple experiment viewer (MeV) 4.9.0 software. Amplification was performed using an ABI 7500 Sequence Detector System (Thermo Fisher Scientific).
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc.). For comparisons, ANOVA test and Bonferroni post-test or Student t test were used. A p value < 0.05 was considered as statistically significant. All pairs were analyzed and statistically significant differences are indicated.
Thoennissen, N. H. et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 115, 2882–2890 (2010).
Barbui, T. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 32, 1057–1069 (2018).
Campbell, P. J. & Green, A. R. The myeloproliferative disorders. N Engl J Med. 355, 2452–2466 (2006).
Delhommeau, F. et al. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci. 63, 2939–2953 (2006).
Levine, R. L., Pardanani, A., Tefferi, A. & Gilliland, D. G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 7, 673–683 (2007).
Pardanani, A. et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 25, 218–225 (2011).
Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 366, 787–798 (2012).
Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 366, 799–807 (2012).
Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 372, 426–435 (2015).
Machado-Neto, J. A. et al. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. Oncotarget. 6, 29573–29584 (2015).
Steinmetz, M. O. & Prota, A. E. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. Trends Cell Biol (2018).
Borisa, A. C. & Bhatt, H. G. A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. Eur J Med Chem. 140, 1–19 (2017).
Gavriilidis, P., Giakoustidis, A. & Giakoustidis, D. Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review. J Clin Med Res. 7, 742–751 (2015).
Matthews, N., Visintin, C., Hartzoulakis, B., Jarvis, A. & Selwood, D. L. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther. 6, 109–120 (2006).
Ikezoe, T. et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther. 6, 1851–1857 (2007).
McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 16, 483–489 (2010).
Lee, Y. R. et al. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J Biomed Sci. 19, 9 (2012).
Kuo, C. H. et al. Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells. Breast Cancer. 21, 358–369 (2014).
Piccoli, M. et al. The synthetic purine reversine selectively induces cell death of cancer cells. J Cell Biochem. 113, 3207–3217 (2012).
Meyer, S. C. et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 28, 15–28 (2015).
Rodrigues Alves, A. P. et al. Reversine triggers mitotic catastrophe and apoptosis in K562 cells. Leuk Res. 48, 26–31 (2016).
Sumi, K., Tago, K., Kasahara, T. & Funakoshi-Tago, M. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. FEBS Lett. 585, 1884–1890 (2011).
Wen, Q. J. et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 21, 1473–1480 (2015).
Pham, H. T. T. et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 128, 387–401 (2018).
Skov, V. et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 87, 54–60 (2011).
Hsieh, T. C., Traganos, F., Darzynkiewicz, Z. & Wu, J. M. The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells. Int J Oncol. 31, 1293–1300 (2007).
D’Alise, A. M. et al. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther. 7, 1140–1149 (2008).
Lowenberg, B., van Putten, W. L., Touw, I. P., Delwel, R. & Santini, V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med. 328, 614–619 (1993).
Yan, Y. et al. Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias. J Hematol Oncol. 2, 51 (2009).
Li, G. et al. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood. 115, 1416–1424 (2010).
Sepulveda, P., Encabo, A., Carbonell-Uberos, F. & Minana, M. D. BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death Differ. 14, 378–380 (2007).
Guo, J. et al. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. PLoS One. 10, e0114363, https://doi.org/10.1371/journal.pone.0114363 (2015).
Martin, P. & Papayannopoulou, T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science. 216, 1233–1235 (1982).
Uozumi, K. et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia. 14, 142–152 (2000).
Gabler, K. et al. Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. J Cell Mol Med. 17, 265–276 (2013).
Dawson, M. A. et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol. 150, 46–57 (2010).
Santaguida, S., Tighe, A., D’Alise, A. M., Taylor, S. S. & Musacchio, A. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol. 190, 73–87 (2010).
Jemaa, M. et al. Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1. Sci Rep. 8, 11821 (2018).
Oktay, K., Buyuk, E., Oktem, O., Oktay, M. & Giancotti, F. G. The c-Jun N-terminal kinase JNK functions upstream of Aurora B to promote entry into mitosis. Cell Cycle. 7, 533–541 (2008).
Saurin, A. T., van der Waal, M. S., Medema, R. H., Lens, S. M. & Kops, G. J. Aurora B potentiates Mps1 activation to ensure rapid checkpoint establishment at the onset of mitosis. Nat Commun. 2, 316, https://doi.org/10.1038/ncomms1319 (2011).
This study was supported by the grant #2017/24993-0, São Paulo Research Foundation (FAPESP), and grant #402587/2016-2, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The authors thanks Fernanda T. Udinal, from the Hemocentro Foundation of Ribeirão Preto, São Paulo, Brazil, for the English language review.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lima, K., Carlos, J.A.E.G., Alves-Paiva, R. et al. Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms. Sci Rep 9, 9895 (2019). https://doi.org/10.1038/s41598-019-46163-2
Scientific Reports (2021)
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia
Cellular Oncology (2020)